Every person,
every team,
every project,
every input
adds value.
We are one company, united by shared expertise, shared experience and a shared purpose to Engineer better treatments. Every person, team and part of the business contributes to that purpose in different ways. Whether we are engineering new technologies, ensuring quality, navigating regulation, supporting customers, growing the business, enabling our teams or advancing our own innovation, we are focused on the same thing: turning innovations into better treatments.
Every customer,
every advancement,
every outcome
made better.
The expertise we offer today was earned through solving complex challenges, bringing innovative treatments to market and continually learning from every success, every setback and every breakthrough.
Insights gained in one part of the business strengthens every other, adding to the expertise we bring to every new opportunity.
That is what makes Emblation different.
We can help unlock
the value of your ideas.
Get in touch
Every milestone
2008
Emblation founded in Scotland by microwave engineers Gary Beale and Eamon McErlean
2009
Ken Lewandowski becomes Chairman. Investment from members of Stirling business community
2009
First hyperthermic 8GHz microwave system developed
2010
Prototype high-powered microwave ablation system developed
2012
Emblation secures CE accreditation for SwiftTM hyperthermic microwave system
2013
OEM manufacturing of high-powered microwave ablation system begins
2016
SwiftTM launches into UK podiatry
2017
OEM manufacturing of 2nd generation of ablation systems begins
2018
Emblation announces FDA clearance for SwiftTM in USA
2019
Emblation enters USA, Europe and Australia markets with SwiftTM
2021
Investment from Apposite Capital.
2023
Emblation moves to new corporate headquarters in Stirling, Scotland
2024
SwiftProTM launches in USA
2024
500,000th Swiftip sold
2025
SwiftProTM launches in UK, Canada and Australia, with specific indications for the treatment of Common and Plantar Warts, and Actinic Keratosis
2025
Emblation secures second FDA 510(k) clearance for SwiftTM & SwiftProTM systems for the treatment of Common and Plantar Warts
2025
Emblation opens US office in Lincoln RI
2026
Emblation launches SwiftscopeTM companion app to SwiftProTM
We are the creators of Swift, a hyperthermic treatment which is redefining skin therapy for warts, verrucas, fungal nails and beyond. Used across 24+ countries it is the only treatment that truly works.
Emblation leadership team
Ian Stevens
Chief Executive Office
Alan McKenna
Chief Financial Officer
Eamon McErlean
Founder & Chief Technology Officer
Tom Daniells
Vice-President Sales & Marketing North America
Melissa Peloquin
Vice-President Operations North America
Brian McMullen
Director of Operations UK & ROW
Shelley Reilly
Director of Sales & Marketing UK & ROW
Matt Kidd
Director of Medical Affairs
Neil McGonigle
Director of Engineering
Emblation board
Ken Lewandowski
Chairman
Malcolm Snowie
Non Executive Director
Rory Pope
Non Executive Director
Ian Stevens
Chief Executive Officer
Alan McKenna
Chief Financial Officer
Every person, every partner.
Job opportunities
What we do changes lives. Want to be part of it?
We don't have any vacancies at the moment. Please check back for future opportunities.
Partners
Medical research always involves great minds thinking together. We are always seeking partners – like-minded companies that want to work with us.
News and events
